Iron chelation as therapy for HIV and Mycobacterium tuberculosis co-infection under conditions of iron overload

被引:31
作者
Meyer, Debra [1 ]
机构
[1] Univ Johannesburg, Dept Biochem, ZA-2006 Auckland Pk, Gauteng Prov, South Africa
关键词
D O I
10.2174/138161206777442164
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Iron chelators, as treatment for conditions of iron overload, have implications for AIDS and tuberculosis (TB) since excess iron in the system assists HIV and Mycobacterium tuberculosis (M.tb) multiplication. Excess iron, especially due to dietary habits, is almost as common in sub-Saharan Africa as infections by the two organisms. That HIV and M.tb influence each other's replication during co-infection is well established, but in vitro evaluations of concurrent infection of the two under conditions of iron overload and determining whether chelators reverse the effect. are limited. This review provides brief commentary on the possibility of iron chelators presently in clinical use influencing simultaneous HIV-M.tb infections during iron loading and the feasibility of evaluating this in vitro.
引用
收藏
页码:1943 / 1947
页数:5
相关论文
共 49 条
[1]   Genotypic and phenotypic heterogeneity of African Americans with primary iron overload [J].
Barton, JC ;
Acton, RT ;
Rivers, CA ;
Bertoli, LF ;
Gelbart, T ;
West, C ;
Beutler, E .
BLOOD CELLS MOLECULES AND DISEASES, 2003, 31 (03) :310-319
[2]   Ferroportin 1 (SCL40A1) variant associated with iron overload in African-Americans [J].
Beutler, E ;
Barton, JC ;
Felitti, VJ ;
Gelbart, T ;
West, C ;
Lee, PL ;
Waalen, J ;
Vulpe, C .
BLOOD CELLS MOLECULES AND DISEASES, 2003, 31 (03) :305-309
[3]   Double-edged effect of Vγ/Vδ2 T lymphocytes on viral expression in an in vitro model of HIV-1/mycobacteria co-infection [J].
Biswas, P ;
Ferrarini, M ;
Mantelli, B ;
Fortis, C ;
Poli, G ;
Lazzarin, A ;
Manfredi, AA .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2003, 33 (01) :252-263
[4]  
Bornman L, 1999, J CELL PHYSIOL, V178, P1
[5]  
Budihna M, 2005, NEOPLASMA, V52, P165
[6]   TUBERCULOSIS IN PATIENTS WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME - CLINICAL-FEATURES, RESPONSE TO THERAPY, AND SURVIVAL [J].
CHAISSON, RE ;
SCHECTER, GF ;
THEUER, CP ;
RUTHERFORD, GW ;
ECHENBERG, DF ;
HOPEWELL, PC .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1987, 136 (03) :570-574
[8]   Microplate Alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium [J].
Collins, LA ;
Franzblau, SG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (05) :1004-1009
[9]  
Comis R L, 1992, Semin Oncol, V19, P64
[10]   The iron chelator L1 potentiates oxidative DNA damage in iron-loaded liver cells [J].
Cragg, L ;
Hebbel, RP ;
Miller, W ;
Solovey, A ;
Selby, S ;
Enright, H .
BLOOD, 1998, 92 (02) :632-638